Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Skin Res Technol ; 30(6): e13793, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38899793

RESUMO

BACKGROUND: To evaluate the efficacy and safety of stromal vascular fraction (SVF), platelet rich plasma (PRP), and 1064-nm Q-switched Nd:YAG laser in reducing nanofat treated dark circles and wrinkles under the eyes. METHOD: This study was a single-blinded randomized clinical trial conducted on patients with suborbital darkening under the eyes that randomly divided into control and case groups. In the control group, 15 patients were treated with one session of nanofat injection only, and five patients of each intervention groups received one session of nanofat+SVF injection, nanofat+PRP injection, and nanofat injection+Nd:YAG laser, respectively. Assessments methods were (1) evaluation of the degree of darkness and repair under the eyes by a blinded dermatologist based on clinical photographs, (2) investigating patient satisfaction, (3) using biometric variables for color, thickness, and density of the skin (only 3 months after the treatment), and (4) recording the possible adverse effects. CONCLUSION: In terms of the extent of reduction in the intensity of darkness under the eyes, the combined treatment of nanofat injection together with SVF, PRP, and Nd:YAG laser had a much greater therapeutic effect than nanofat injection alone. In all three groups of combined treatments, patients were 100% satisfied. In terms of biometric variables, amount of changes in colorimeter, complete and dermal thickness, complete and dermal density, between the different groups was statistically significant. The use of combined treatments including nanofat with SVF injection, PRP, and 1064 Q-switched Nd:YAG laser may be more effective than nanofat alone, in reducing infraorbital dark circles and wrinkles.


Assuntos
Técnicas Cosméticas , Lasers de Estado Sólido , Plasma Rico em Plaquetas , Envelhecimento da Pele , Humanos , Feminino , Lasers de Estado Sólido/uso terapêutico , Pessoa de Meia-Idade , Método Simples-Cego , Adulto , Técnicas Cosméticas/instrumentação , Resultado do Tratamento , Masculino , Satisfação do Paciente
2.
J Complement Integr Med ; 21(2): 191-196, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38282343

RESUMO

OBJECTIVES: Oxidative stress has a key role in the diabetes pathogenesis and complications. Berberis vulgaris is known in folk medicine for curing several diseases. The current research aimed to assess the influences of Berberis vulgaris fruit extract against oxidative stress in streptozotocin-induced diabetic rats. METHODS: Streptozotocin (60 mg/kg, ip) was injected to male rats. After diabetes confirmation, animals received the Berberis vulgaris fruit extract daily at amounts of 3.5 and 7.5 % of drinking water (v/v) for six weeks. Total thiol and lipid peroxidation levels were assessed in the serum, liver, kidney and spleen at the end of the study. RESULTS: Diabetic rats exhibited hyperglycemia along with enhancement of lipid peroxidation levels in the serum, liver, kidney and spleen, and decrement of total thiol content in the kidney and liver tissues. Chronic administration of Berberis vulgaris fruit extract at amount of 3.5 % of drinking water decreased the lipid peroxidation level in the serum and liver, and enhanced total thiol level in the liver and kidney. CONCLUSIONS: Berberis vulgaris fruit extract exerts antioxidant activity in the serum, liver and kidney organs of diabetic rats. Therefore, it might be used in the prevention and control of diabetes complications.


Assuntos
Antioxidantes , Berberis , Diabetes Mellitus Experimental , Frutas , Rim , Peroxidação de Lipídeos , Fígado , Estresse Oxidativo , Extratos Vegetais , Ratos Wistar , Animais , Berberis/química , Extratos Vegetais/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Masculino , Diabetes Mellitus Experimental/tratamento farmacológico , Frutas/química , Rim/efeitos dos fármacos , Rim/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Ratos , Peroxidação de Lipídeos/efeitos dos fármacos , Antioxidantes/farmacologia
3.
RNA Biol ; 18(sup2): 747-756, 2021 11 12.
Artigo em Inglês | MEDLINE | ID: mdl-34793290

RESUMO

Breast cancer (BC) as a leading cause of cancer death among women, exhibits a wide range of genetic heterogeneity in affected individuals. Satisfactory management of BC depends on early diagnosis and proper monitoring of patients' response to therapy. In this study, we aimed to assess the relation between the expression patterns of blood-based microRNAs (miRNAs) with demographic characteristics of the patients with BC in an attempt to find novel diagnostic markers for BC with acceptable precision in clinical applications. To this end, we performed comprehensive statistical analysis of the data of the Cancer Genome Atlas (TCGA) database and the blood miRNome dataset (GSE31309). As a result, 21 miRNAs were selected for experimental verification by quantitative RT-PCR on blood samples of 70 BC patients and 60 normal individuals (without any lesions or benign breast diseases). Statistical one-way ANOVA revealed no significant difference in the blood levels of the selected miRNAs in BC patients compared to any lesions or benign breast diseases. However, the multi-marker panel consisting of hsa-miR-106b-5p, -126-3p, -140-3p, -193a-5p, and -10b-5p could detect early-stages of BC with 0.79 sensitivity, 0.86 specificity and 0.82 accuracy. Furthermore, this multi-marker panel showed the potential of detecting benign breast diseases from BC patients with 0.67 sensitivity, 0.80 specificity, and 0.74 accuracy. In conclusion, these data indicate that the present panel might be considered an asset in detecting benign breast disease and BC.


Assuntos
Biomarcadores , Doenças Mamárias/diagnóstico , Doenças Mamárias/genética , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/genética , MicroRNA Circulante , MicroRNAs/genética , Biomarcadores Tumorais , Doenças Mamárias/sangue , Neoplasias da Mama/sangue , Diagnóstico Diferencial , Detecção Precoce de Câncer , Feminino , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Biópsia Líquida/métodos , MicroRNAs/sangue , Estadiamento de Neoplasias , Fosfatidilinositol 3-Quinases/metabolismo , Prognóstico , Proteínas Proto-Oncogênicas c-akt/metabolismo , Curva ROC , Reação em Cadeia da Polimerase em Tempo Real , Sensibilidade e Especificidade , Transdução de Sinais
4.
Vasc Endovascular Surg ; 53(7): 609-612, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31309863

RESUMO

The subclavian steal syndrome (SSS), also called subclavian steal steno-occlusive disease, is defined as reversal of the vertebral artery flow secondary to significant hemodynamically ipsilateral occlusion or stenosis of the proximal subclavian artery. It is usually seen secondary to atherosclerosis and aberrant right subclavian artery (ARSA), resulting in SSS which is even less common. Aberrant right subclavian artery is a kind of vascular anomaly associated with coarctation of the aorta (CoA). It usually originates from the descending aorta distal to the site of CoA. Here, we present a young man who was a case of ARSA and CoA. He developed SSS after transcatheter aortic stenting secondary to unusual origin of ARSA from the site of CoA. Awareness of this rare anomaly helps to overcome this complication in patients undergoing interventional stenting for CoA and ARSA with anomalous origin.


Assuntos
Coartação Aórtica/terapia , Anormalidades Cardiovasculares/complicações , Procedimentos Endovasculares/instrumentação , Stents , Artéria Subclávia/anormalidades , Adulto , Coartação Aórtica/complicações , Coartação Aórtica/diagnóstico por imagem , Coartação Aórtica/fisiopatologia , Aortografia/métodos , Anormalidades Cardiovasculares/diagnóstico por imagem , Anormalidades Cardiovasculares/fisiopatologia , Anormalidades Cardiovasculares/cirurgia , Angiografia por Tomografia Computadorizada , Procedimentos Endovasculares/efeitos adversos , Humanos , Masculino , Artéria Subclávia/diagnóstico por imagem , Artéria Subclávia/fisiopatologia , Artéria Subclávia/cirurgia , Síndrome do Roubo Subclávio/diagnóstico por imagem , Síndrome do Roubo Subclávio/etiologia , Síndrome do Roubo Subclávio/fisiopatologia , Resultado do Tratamento , Ultrassonografia Doppler em Cores
5.
J Med Food ; 16(3): 206-10, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23437790

RESUMO

The aim of the present study was to investigate the antihyperglycemic and protective potential of crocin, a pharmacologically active constituent of Crocus sativus L., in streptozotocin-induced diabetic rats. Rats were administered crocin intraperitoneally at doses of 15, 30, and 60 mg/kg of body weight for 6 weeks. The levels of thiobarbituric acid reactive substance (TBARS) and total thiol (SH) groups were measured in the liver and kidney at the end of 6 weeks. Under our experimental conditions, crocin at a dose of 60 mg/kg was found to significantly reduce the blood glucose level in diabetic animals. In addition, there was a significant increase in TBARS levels and decreased total thiol concentrations in the liver and kidney of diabetic animals. Crocin, at doses of 30 and 60 mg/kg, appears to exert an antioxidative activity demonstrated by a lowering of lipid peroxidation levels in these organs. In conclusion, our findings suggest that crocin has the hypoglycemic and antioxidative properties in streptozotocin-induced diabetes and it may be useful in the management of diabetic patients.


Assuntos
Antioxidantes/uso terapêutico , Carotenoides/uso terapêutico , Crocus/química , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Fitoterapia , Extratos Vegetais/uso terapêutico , Animais , Antioxidantes/farmacologia , Glicemia/metabolismo , Carotenoides/farmacologia , Diabetes Mellitus Experimental/metabolismo , Hipoglicemiantes/farmacologia , Rim/efeitos dos fármacos , Rim/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Extratos Vegetais/farmacologia , Ratos , Ratos Wistar , Compostos de Sulfidrila/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
6.
Indian J Pharmacol ; 44(3): 304-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22701236

RESUMO

INTRODUCTION: Alcea rosea L. is used in Asian folk medicine as a remedy for a wide range of ailments. The aim of the present study was to investigate the effect of hydroalcoholic extract of Alcea rosea roots on ethylene glycol-induced kidney calculi in rats. MATERIALS AND METHODS: Male Wistar rats were randomly divided into control, ethylene glycol (EG), curative and preventive groups. Control group received tap drinking water for 28 days. Ethylene glycol (EG), curative and preventive groups received 1% ethylene glycol for induction of calcium oxalate (CaOx) calculus formation; preventive and curative subjects also received the hydroalcoholic extract of Alcea rosea roots in drinking water at dose of 170 mg/kg, since day 0 or day 14, respectively. Urinary oxalate concentration was measured by spectrophotometer on days 0, 14 and 28. On day 28, the kidneys were removed and examined histopathologically under light microscopy for counting the calcium oxalate deposits in 50 microscopic fields. RESULTS: In both preventive and curative protocols, treatment of rats with hydroalcoholic extract of Alcea rosea roots significantly reduced the number of kidney calcium oxalate deposits compared to ethylene glycol group. Administration of Alcea rosea extract also reduced the elevated urinary oxalate due to ethylene glycol. CONCLUSION: Alcea rosea showed a beneficial effect in preventing and eliminating calcium oxalate deposition in the rat kidney. This effect is possibly due to diuretic and anti-inflammatory effects or presence of mucilaginous polysaccharides in the plant. It may also be related to lowering of urinary concentration of stone-forming constituents.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...